Systemic upregulation of PDGF-B in patients with neovascular AMD

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 1, 2014, Pages 337-344

  Zehetner, Claus ^a   Kirchmair, Rudolf ^b   Neururer, Sabrina B ^a   Kralinger, Martina T ^a   Bechrakis, Nikolaos E ^a   Kieselbach, Gerhard F ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Diabetic retinopathy; HIF 1; Neovascular age related macular degeneration; PDGF B; Plasma levels; TNF

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; PLATELET DERIVED GROWTH FACTOR B; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEPTOR UPREGULATION; RETINA MACULA AGE RELATED DEGENERATION; VERY ELDERLY;

DIABETIC RETINOPATHY; HIF-1; NEOVASCULAR AGE-RELATED MACULAR DEGENERATION; PDGF-B; PLASMA LEVELS; TNF-Α;

BIOLOGICAL MARKERS; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FOLLOW-UP STUDIES; HUMANS; MACULAR DEGENERATION; MACULAR EDEMA; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-SIS; RETINAL NEOVASCULARIZATION; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84896699328     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-12978     Document Type: Article

References (47)

1. Campochiaro PA. Ocular neovascularization. J Mol Med (Berl). 2013;91:311-321.
2. Robbins SG, Mixon RN, Wilson DJ, et al. Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. Invest Ophthalmol Vis Sci. 1994;35:3649-3663.
3. Betsholtz C. Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev. 2004;15:215-228.
4. Wilkinson-Berka JL, Babic S, De Gooyer T, et al. Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy. Am J Pathol. 2004;164: 1263-1273.
5. Hall AP. Review of the pericyte during angiogenesis and its role in cancer and diabetic retinopathy. Toxicol Pathol. 2006;34: 763-775.
6. Shen J, Vil MD, Zhang H, et al. An antibody directed against PDGF receptor beta enhances the antitumor and the antiangiogenic activities of an anti-VEGF receptor 2 antibody. Biochem Biophys Res Commun. 2007;357:1142-1147.
7. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003; 111:1287-1295.
8. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development. 1998;125:1591-1598.
9. Al-Gayyar MM, Elsherbiny NM. Contribution of TNF-alpha to the development of retinal neurodegenerative disorders. Eur Cytokine Netw. 2013;24:27-36.
10. Swaroop A, Chew EY, Rickman CB, Abecasis GR. Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration. Annu Rev Genomics Hum Genet. 2009;10:19-43.
11. Jung Y, Isaacs JS, Lee S, Trepel J, Liu ZG, Neckers L. Hypoxiainducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation. Biochem J. 2003;370: 1011-1017.
12. Oh H, Takagi H, Takagi C, et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1999;40:1891-1898.
13. Picchi A, Gao X, Belmadani S, et al. Tumor necrosis factoralpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ Res. 2006;99:69-77.
14. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol. 2008;30:65-84.
15. Koskela UE, Kuusisto SM, Nissinen AE, Savolainen MJ, Liinamaa MJ. High vitreous concentration of IL-6 and IL-8, but not of adhesion molecules in relation to plasma concentrations in proliferative diabetic retinopathy. Ophthalmic Res. 2013;49: 108-114.
16. Zhou J, Wang S, Xia X. Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. Curr Eye Res. 2012;37:416-420.
17. Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol. 2010; 94:1215-1218.
18. Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol. 2013;97:454-459.
19. Carneiro AM, Costa R, Falcao MS, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol. 2012;90:e25-e30.
20. Proetzel G, Roopenian DC. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies [published online ahead of print July 16, 2013]. Methods. doi:10.1016/j.ymeth.2013.07.005.
21. Saishin Y, Saishin Y, Takahashi K, et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol. 2003; 195:241-248.
22. Sfikakis PP, Grigoropoulos V, Emfietzoglou I, et al. Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study. Diabetes Care. 2010;33:1523-1528.
23. Markomichelakis NN, Theodossiadis PG, Sfikakis PP. Regression of neovascular age-related macular degeneration following infliximab therapy. Am J Ophthalmol. 2005;139:537-540.
24. Wilkinson CP, Ferris FL III, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110: 1677-1682.
25. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care. 2002;25:275-278.
26. Wang GL, Semenza GL. General involvement of hypoxiainducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A. 1993;90:4304-4308.
27. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiolo Rev. 1999;79: 1283-1316.
28. Raines EW. PDGF and cardiovascular disease. Cytokine Growth Factor Rev. 2004;15:237-254.
29. Vingerling JR, Dielemans I, Bots ML, Hofman A, Grobbee DE, de Jong PT. Age-related macular degeneration is associated with atherosclerosis. The Rotterdam Study. Am J Epidemiol. 1995;142:404-409.
30. Klein R, Cruickshanks KJ, Myers CE, et al. The relationship of atherosclerosis to the 10-year cumulative incidence of agerelated macular degeneration: the Beaver Dam Studies. Ophthalmology. 2013;120:1012-1019.
31. Vine AK, Stader J, Branham K, Musch DC, Swaroop A. Biomarkers of cardiovascular disease as risk factors for agerelated macular degeneration. Ophthalmology. 2005;112: 2076-2080.
32. Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 1991;253:1129-1132.
33. Khachigian LM, Anderson KR, Halnon NJ, Gimbrone MA Jr, Resnick N, Collins T. Egr-1 is activated in endothelial cells exposed to fluid shear stress and interacts with a novel shearstress-response element in the PDGF A-chain promoter. Arterioscl Thromb Vasc Biol. 1997;17:2280-2286.
34. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res. 2005;97:512-523.
35. Antonetti D. Eye vessels saved by rescuing their pericyte partners. Nat Med. 2009;15:1248-1249.
36. Geraldes P, Hiraoka-Yamamoto J, Matsumoto M, et al. Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med. 2009;15:1298-1306.
37. Enge M, Bjarnegard M, Gerhardt H, et al. Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy. EMBO J. 2002;21:4307-4316.
38. Ashton N. Studies of the retinal capillaries in relation to diabetic and other retinopathies. Br J Ophthalmol. 1963;47: 521-538.
39. Chaturvedi N, Fuller JH, Pokras F, Rottiers R, Papazoglou N, Aiello LP. Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition. Diabet Med. 2001; 18:288-294.
40. Zehetner C, Kirchmair R, Kralinger M, Kieselbach G. Correlation of vascular endothelial growth factor plasma levels and glycemic control in patients with diabetic retinopathy. Acta Ophthalmol. 2013;91:e470-e473.
41. McDermott MF. TNF and TNFR biology in health and disease. Cell Mol Biol (Noisy-le-grand). 2001;47:619-635.
42. Grant MB, Afzal A, Spoerri P, Pan H, Shaw LC, Mames RN. The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs. 2004;13:1275-1293.
43. Mirshahi A, Hoehn R, Lorenz K, Kramann C, Baatz H. Antitumor necrosis factor alpha for retinal diseases: current knowledge and future concepts. J Ophthalmic Vis Res. 2012;7:39-44.
44. Theodossiadis PG, Markomichelakis NN, Sfikakis PP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina. 2007;27:399-413.
45. Limb GA, Hollifield RD, Webster L, Charteris DG, Chignell AH. Soluble TNF receptors in vitreoretinal proliferative disease. Invest Ophthalmol Vis Sci. 2001;42:1586-1591.
46. Derevjanik NL, Vinores SA, Xiao WH, et al. Quantitative assessment of the integrity of the blood-retinal barrier in mice. Invest Ophthalmol Vis Sci. 2002;43:2462-2467.
47. Hong S, Kim CY, Lee JE, Seong GJ. Agmatine protects cultured retinal ganglion cells from tumor necrosis factor-alpha-induced apoptosis. Life Sci. 2009;84:28-32.